ArticleJournal of hepatocellular carcinoma2025
Impact of Cytokeratin 19 Expression on the Outcomes of Unresectable Hepatocellular Carcinoma Treated with Targeted Therapy and Immunotherapy: A Propensity Score Matched Analysis.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A habitat radiomics model based on contrast-enhanced MRI for predicting early treatment response to hepatic arterial infusion chemotherapy in patients with unresectable hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytokeratin 19 (CK19) serves as a significant prognostic indicator for hepatocellular carcinoma (HCC). However, it is uncertain if CK19 expression influences the prognosis and effectiveness of treatment in patients undergoing targeted therapy and immunotherapy for unresectable HCC. This study aimed to evaluate the prognostic value of CK19 expression in this patient population. Methods: Patients with unresectable HCC who received combined targeted therapy and immunotherapy between January 2021 and December 2023 were retrospectively analyzed in this study. CK19 expression in tumor biopsy samples from patients before treatments were identified using immunohistochemistry. Propensity score matching (PSM) was conducted in a 1:2 ratio to balance baseline features between the CK19-positive and CK19-negative groups. Survival outcomes were analyzed using the Kaplan-Meier method along with the Cox regression model. Treatment response was evaluated based on mRECIST criteria. Results: A total of 247 patients were included, and 126 were selected after-PSM (43 CK19-positive, 83 CK19-negative), with balanced baseline characteristics. After PSM, the CK19-negative group had a markedly prolonged median OS compared to the CK19-positive group (42.2 months vs 15.6 months, p < 0.001), along with an extended median PFS (28.9 months vs 7.3 months, p < 0.001). The ORR was significantly higher in the CK19-negative group than in the CK19-positive group (59.0% vs 18.6%, p < 0.001), and the DCR was also superior (96.4% vs 79.1%, p = 0.005). Multivariate Cox analysis found CK19 expression as an independent factor predicting OS and PFS. Conclusion: In patients with unresectable HCC undergoing targeted therapy and immunotherapy, CK19 expression correlated with poorer survival outcomes and diminished therapeutic response. CK19 may serve as a valuable biomarker for prognosis and treatment stratification in advanced HCC, and CK19 screening may be incorporated into clinical trial stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.